Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pluristem Therapeutics Inc (NASDAQ:PSTI)

1.77
Delayed Data
As of Oct 20
 -0.035 / -1.94%
Today’s Change
1.04
Today|||52-Week Range
2.02
+23.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$172.0M

Company Description

Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The company focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others. Its products include PLacental eXpanded, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Contact Information

Pluristem Therapeutics, Inc.
MATAM Advanced Technology Park
Haifa Haifa 31905
P:972747108600
Investor Relations:
972747108721

Employees

Shareholders

Other institutional3.67%
Individual stakeholders12.04%
Mutual fund holders1.41%

Top Executives

Zami AbermanChairman & Co-Chief Executive Officer
Yaky YanayPresident, Co-Chief Executive Officer & Director
Sagi MoranVice President-Operations
Erez EgoziChief Financial Officer, Secretary & Treasurer
Esther Lukasiewicz-HagaiVice President-Clinical & Medical Affairs